Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EpiminderASX:EPI +4.55%8 EV-to-EBITDA is 4.27 as of Aug. 20, 2026. GuruFocus rates ASX:EPI with a GF Score™ of 8/100. Among 515 Medical Devices & Instruments companies, Epiminder ranks better than 92.23% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Epiminder's enterprise value is A$-89.40 Mil.
Epiminder's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-20.93 Mil. Therefore, Epiminder's EV-to-EBITDA for today is 4.27.
The historical rank and industry rank for Epiminder's EV-to-EBITDA or its related term are showing as below:
ASX:EPI'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 0 Max: 4.27
Current: 4.27
During the past 3 years, the highest EV-to-EBITDA of Epiminder was 4.27. The lowest was 0.00. And the median was 0.00.
ASX:EPI's EV-to-EBITDA is ranked better than 92.23% of 515
companies
in the Medical Devices & Instruments industry
Industry Median: 15.16
vs ASX:EPI: 4.27
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Epiminder's share price for today is A$0.46.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Epiminder's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.254.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Epiminder's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Epiminder EV-to-EBITDA Chart
Epiminder Annual Data
Trend
Jun23
Jun24
Jun25
EV-to-EBITDA
0.00
0.00
0.00
Epiminder Semi-Annual Data
Jun23
Jun24
Jun25
Dec25
EV-to-EBITDA
0.00
0.00
0.00
0.00
ASX:EPI vs ABT, SYK, MDT: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Epiminder's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Epiminder EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Epiminder's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Epiminder's EV-to-EBITDA falls into.
Epiminder's current Enterprise Value is A$-89.40 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Epiminder's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-20.93 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Epiminder (ASX:EPI) has a EV-to-EBITDA of 4.27 as of Aug. 20, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Epiminder. According to the industry distribution chart, Epiminder ranks #40 out of 515 companies in the Medical Devices & Instruments industry, placing it in the top 7.8%.
Is Epiminder's EV-to-EBITDA too high?
Epiminder's current EV-to-EBITDA is 4.27. The Medical Devices & Instruments industry median EV-to-EBITDA is 15.16. Epiminder's value of 4.27 is 71.8% below this industry median. Based on the distribution chart, Epiminder ranks #40 out of 515 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Epiminder has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Epiminder's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Epiminder ranks #40 out of 515 companies for EV-to-EBITDA. This places Epiminder in the top 8% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 15.16. Epiminder's value of 4.27 is 71.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 15.16, based on 515 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Epiminder's current EV-to-EBITDA of 4.27 is 71.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Epiminder. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 15.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Epiminder's current EV-to-EBITDA is 4.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Epiminder stock overvalued right now?
Epiminder (ASX:EPI) has a current EV-to-EBITDA of 4.27. The current EV-to-EBITDA is 4.27 and 71.8% below the Medical Devices & Instruments industry median of 15.16. Epiminder's overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Epiminder (ASX:EPI), the current EV-to-EBITDA is 4.27 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Epiminder Ltd is a medical device and information solutions company focused on developing diagnostic and treatment tools for epilepsy. Its system is a sub-scalp device for continuous monitoring of electrographic brain activity and a set of information solutions, providing patients and their healthcare professionals with detailed data over an extended period.
8GF Score
Get the complete analysis for ASX:EPI
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EPI has been successfully added to your 
